Lilly Asia Ventures
Andiely Lu, M.D., is an Investment Manager with Lilly Asia Ventures (LAV). Prior to joining LAV, Andiely worked at L.E.K. Consulting as a core member of L.E.K. Asia-Pacific Life Sciences Practice, where he led and supported multiple projects across biotech and medtech sectors. Prior to that, Andiely was a PRC certified physician and served at Tongji Hospital Huazhong University of Science and Technology (HUST). Andiely holds an M.D. in GI Surgery and an M.B.B.S. in Clinical Medicine from Tongji Medical College of HUST.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.